Skip to main content
MDRX
OTC Technology

Veradigm Files Overdue 10-Ks, Reports $291.6M Net Loss on Declining Revenue

Reported by Wiseek News
Sentiment info
Negative
Importance info
8
Price
$4.75
Mkt Cap
$516.8M
52W Low
$3
52W High
$6
Market data snapshot near publication time

Summary

Veradigm has filed its overdue 2023 and 2024 Form 10-Ks, a critical step towards resolving compliance issues and seeking relisting on a national exchange. However, the financial results are significantly negative, with 2024 revenue declining to $594.4 million from $626.0 million in 2023, and adjusted EBITDA falling to $94.1 million from $131.5 million. The company reported a substantial net loss of $291.6 million for 2024, a sharp reversal from a $49.2 million net income in 2023. Preliminary 2025 revenue guidance of $584-$589 million indicates further declines. The company is now focused on completing 2025 filings and achieving a national exchange listing.

At the time of this announcement, MDRX was trading at $4.75 on OTC in the Technology sector, with a market capitalization of approximately $516.8M. The 52-week trading range was $3.00 to $6.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

MDRX - Latest Insights

MDRX
May 26, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
MDRX
Feb 17, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
MDRX
Feb 02, 2026, 4:23 PM EST
Filing Type: 8-K
Importance Score:
7